OTLK

Outlook Therapeutics Inc

Jun 05 • 10:00AM ET

0.7987

+0.0039 0.49 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: XLO RADX RNTX TELO INDP GLSI PALI PRLD RZLT TARA

Index	-	P/E	-	EPS (ttm)	-1.09	Insider Own	43.50%	Shs Outstand	104.61M	Perf Week	9.41%
Market Cap	96.53M	Forward P/E	-	EPS next Y	-0.26	Insider Trans	21.01%	Shs Float	45.05M	Perf Month	244.56%
Enterprise Value	115.97M	PEG	-	EPS next Q	-0.11	Inst Own	9.15%	Short Float	20.17%	Perf Quarter	92.92%
Income	-43.44M	P/S	63.93	EPS this Y	71.40%	Inst Trans	6.43%	Short Ratio	0.64	Perf Half Y	-59.46%
Sales	1.51M	P/B	-	EPS next Y	48.28%	ROA	-125.04%	Short Interest	9.09M	Perf YTD	-49.45%
Book/sh	-0.28	P/C	12.46	EPS next 5Y	-	ROE	-	52W High	3.39 -76.44%	Perf Year	-57.29%
Cash/sh	0.06	P/FCF	-	EPS past 3/5Y	33.96% 33.18%	ROIC	-	52W Low	0.16 395.78%	Perf 3Y	-97.72%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	63.07%	Volatility	17.96% 18.11%	Perf 5Y	-98.46%
Dividend TTM	-	EV/Sales	76.80	EPS Y/Y TTM	86.28%	Oper. Margin	-4824.52%	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.45	Sales Y/Y TTM	-	Profit Margin	-2885.82%	RSI (14)	80.45	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.54	EPS Q/Q	-107.59%	SMA20	71.91%	Beta	0.98	Target Price	4.17
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	136.45%	Rel Volume	1.49	Prev Close	0.79
Employees	17	LT Debt/Eq	-	Earnings	May 15 AMC	SMA200	-12.63%	Avg Volume	14.30M	Price	0.80
IPO	Jun 14, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-32.01% -97.08%	Trades		Volume	2,621,371	Change	0.49%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-26	Downgrade	BTIG Research	Buy → Neutral
Aug-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-25	Downgrade	Guggenheim	Buy → Neutral
Dec-02-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Mar-27-24	Upgrade	BTIG Research	Neutral → Buy	$50
Feb-15-24	Upgrade	Chardan Capital Markets	Neutral → Buy	$3
Jan-25-24	Upgrade	Guggenheim	Neutral → Buy
Dec-27-23	Upgrade	CapitalOne	Equal Weight → Overweight	$5
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral	$5 → $1
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$4.50 → $1
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight	$5
Apr-03-23	Initiated	Guggenheim	Buy	$5
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight	$4
Oct-31-22	Initiated	BTIG Research	Buy	$7
Sep-13-22	Initiated	Chardan Capital Markets	Buy	$10
Sep-11-19	Initiated	Ladenburg Thalmann	Buy	$9

Show Previous Ratings

Jun-01-26 01:05PM	OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal (Stocktwits) +15.48%
08:46AM	Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
May-28-26 04:00PM	Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +26.39%
01:38PM	OTLK Stock Rocket Nearly 140%: Lytenava Dispute Resolution With FDA Pushes Stock On Track For Best Week On Record (Stocktwits)
May-27-26 01:10AM	Why RDW, TE, OTLK Stocks Posted Double-Digit Gains On Tuesday (Stocktwits) +46.30%
09:08AM	Loading…
May-26-26 09:08AM	OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone Whats Behind This Massive Rally? (Stocktwits) +29.14%
07:00AM	Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
May-15-26 04:05PM	Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-23-26 04:05PM	Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering (GlobeNewswire) +9.83%
Apr-22-26 08:30AM	Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.14%
Apr-21-26 09:05AM	Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire) -13.68%
Apr-07-26 08:50AM	Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab-vikg) Accepted by FDA (GlobeNewswire) +6.18%
Mar-25-26 04:05PM	Outlook Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire)
Mar-24-26 07:00AM	Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -38.06%
Mar-23-26 05:30PM	Outlook Therapeutics Announces Proposed Public Offering (GlobeNewswire) -8.91%
08:05AM	Loading…
Mar-16-26 08:05AM	Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note (GlobeNewswire) -10.69%
Mar-05-26 04:15PM	Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
Feb-19-26 09:00AM	Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA (bevacizumab gamma) in Switzerland (GlobeNewswire) +6.10%
Feb-17-26 09:15AM	Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -13.82%
08:05AM	Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-11-26 08:45AM	Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter (GlobeNewswire) +11.52%
Jan-07-26 09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks) +11.43%
Jan-06-26 08:35AM	Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development (GlobeNewswire)
Jan-02-26 07:29AM	Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks (Investing.com) -58.23%
Jan-01-26 04:35PM	FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present form (TipRanks)
Dec-31-25 04:15PM	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire) -15.28% -58.23%
Dec-26-25 05:00PM	Outlook Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +8.79%
Dec-19-25 09:30AM	Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 (GlobeNewswire)
Dec-16-25 11:39AM	Micron Dominates Barchart's Top 100 with Killer VolumeYour Buy Signal? (Barchart) +13.82%
09:05AM	Loading…
Nov-24-25 09:05AM	Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 08:30AM	Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) +14.84%
Nov-03-25 08:35AM	Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 (GlobeNewswire)
Sep-29-25 08:45AM	Outlook Therapeutics Provides Update on Type A Meeting with FDA (GlobeNewswire) +9.27%
Sep-03-25 08:35AM	Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) (GlobeNewswire)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:35AM	Outlook Therapeutics Requests Type A Meeting with FDA (GlobeNewswire)
Aug-29-25 10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks) -21.91%
09:38AM	Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
Aug-28-25 11:15AM	FDA Rejects Outlook Therapeutics Eye Drug For Second Time (Benzinga) -54.11%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
06:30AM	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +18.38%
Aug-14-25 09:15AM	Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +14.08%
08:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Jul-30-25 05:50AM	New Strong Buy Stocks for July 30th (Zacks)
Jul-24-25 09:00AM	Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase (GlobeNewswire)
Jul-22-25 08:45AM	Outlook Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-01-25 08:05AM	Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer (GlobeNewswire)
Jun-18-25 09:05AM	Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event (GlobeNewswire)
Jun-11-25 05:06AM	Outlooks wet AMD treatment accepted by SMC for NHS Scotland (Pharmaceutical Technology)
Jun-10-25 08:05AM	Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire)
Jun-02-25 07:00AM	Outlook Therapeutics Announces Commercial Launch of LYTENAVA (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD (GlobeNewswire)
May-23-25 06:30AM	Outlook Therapeutics Announces Pricing of $13.0 Million Public Offering (GlobeNewswire)
May-22-25 04:01PM	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
May-15-25 04:01PM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Apr-08-25 08:45AM	Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
Mar-20-25 05:24PM	Outlook Therapeutics files to sell 21.72M shares of common stock for holders (SeekingAlpha)
Feb-28-25 08:05AM	Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration (GlobeNewswire) +8.70%
Feb-19-25 09:00AM	Outlook Therapeutics Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-14-25 08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Feb-04-25 09:05AM	Outlook Therapeutics Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Jan-31-25 08:05AM	Outlook Therapeutics Appoints Faisal G. Sukhtian as Chairman of the Board of Directors (GlobeNewswire)
Jan-23-25 09:05AM	Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD (GlobeNewswire)
Jan-22-25 09:05AM	Outlook Therapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) -8.93%
Jan-16-25 12:09PM	Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug (Benzinga)
06:00AM	Outlook Therapeutics Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial (GlobeNewswire)
Jan-08-25 09:15AM	Outlook Therapeutics Participates in Virtual Investor What This Means Segment (GlobeNewswire) -5.22%
Dec-30-24 07:45AM	Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss (GuruFocus.com) -7.46%
Dec-28-24 10:50PM	Outlook Therapeutics Reports 2024 Financial Results (TipRanks)
08:10AM	Outlook Therapeutics provides ONS-5010/LYTENAVA update (TipRanks)
Dec-27-24 08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire) +18.24%
Dec-13-24 04:30PM	Outlook Therapeutics Streamlines Operations (GlobeNewswire)
Dec-04-24 08:05AM	Outlook Therapeutics Announces NICE Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire) -8.03%
Dec-03-24 04:30PM	Outlook Therapeutics Announces Executive Leadership Transition (GlobeNewswire) -11.08%
Nov-30-24 05:50AM	Outlook Therapeutics price target lowered to $9 from $50 at BTIG (TipRanks)
Nov-27-24 11:08AM	Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial (Pharmaceutical Technology) -65.24%
11:07AM	Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial (Clinical Trials Arena)
09:27AM	Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? (Benzinga)
06:50AM	Outlook Therapeutics Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial (GlobeNewswire)
Nov-06-24 08:05AM	Outlook Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Oct-17-24 09:00AM	Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment (GlobeNewswire)
Sep-16-24 08:05AM	Outlook Therapeutics to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) -8.35%
Sep-13-24 09:05AM	Outlook Therapeutics Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series (GlobeNewswire)
Sep-04-24 08:35AM	Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial (GlobeNewswire) +9.12%
Sep-03-24 08:45AM	Outlook Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -8.30%
Aug-15-24 06:20AM	Q3 2024 Outlook Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-24 07:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire) -5.29%
Aug-12-24 09:05AM	Outlook Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-09-24 07:16AM	Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now? (Insider Monkey)
Aug-07-24 08:35AM	Outlook Therapeutics to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast (GlobeNewswire)
Jul-30-24 09:10AM	Outlook Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-08-24 08:35AM	Outlook Therapeutics Announces UK MHRA Marketing Authorization of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire) +7.38%
Jun-25-24 07:30AM	3 Undervalued Gems Set to Soar 1,000% by 2026 (InvestorPlace)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-12-24 10:00AM	Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series (ACCESSWIRE)
Jun-11-24 09:05AM	Outlook Therapeutics to Present at the Virtual Investor Pitch Conference (GlobeNewswire) +7.92%
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
Jun-06-24 10:30AM	Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor 'What This Means' Segment Hosted by JTC Team (ACCESSWIRE)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

MBARobert Charles Jahr

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Haddadin Yezan Munther	Director	Jun 02 '26	Buy	0.83	29,000	24,145	66,167	Jun 03 06:03 PM
Sukhtian Ghiath M.	Director	May 28 '26	Buy	0.59	8,539,709	5,000,000	22,092,068	Jun 01 09:30 PM
Sukhtian Faisal Ghiath	Director	May 27 '26	Buy	0.41	122,174	50,006	125,574	May 27 03:29 PM
Haddadin Yezan Munther	Director	May 26 '26	Buy	0.44	34,000	14,960	37,167	May 27 03:24 PM
THURMAN RANDY H	Director	May 26 '26	Buy	0.43	5,000	2,145	5,593	May 27 03:20 PM
HILZINGER KURT J	Director	May 26 '26	Buy	0.44	400,000	176,520	423,655	May 27 03:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OTLK

Outlook Therapeutics Inc

Upgrade your Finviz experience